Loading…

OPKO Health, Inc.OPKCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical/Nursing Services

Diversified health care company combining a diagnostics lab (BioReference), a pharmaceutical pipeline and specialty products.

Momentum leader 89
Mkt cap
$1.25B
US dollars, full cap
Free float
51%
of shares outstanding
$/day
$5.73M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-19.9 pp
WACC 10.6%
Hurdle
n/a
no reverse DCF
Next earnings
106 days
4 Mar 2027
Close · USD$1.69
1D+4.3%
1W-1.2%
1M+1.8%
3M+15.8%
6M+37.4%
YTD+34.1%
1Y+33.1%
ATR %5.0%
Beta0.82
52w lowhigh9.1% off high

What OPKO Health does

Diversified health care company combining a diagnostics lab (BioReference), a pharmaceutical pipeline and specialty products.

Collects royalties and milestone payments from partners that sell its drugs, notably Pfizer for the growth hormone Ngenla (somatrogon), while selling Rayaldee itself. Phillip Frost, the chairman, is the largest shareholder.

Products and services

  • BioReference clinical laboratory testing
  • Pharmaceutical products (Rayaldee, somatrogon)
  • Pipeline biotech R&D

Customers

  • Physicians/patients (lab testing)
  • Endocrinology/nephrology patients (pharma products

Where it sits in the supply chain

  • Health care/diagnostics/pharma
  • Diversified health care holding
  • Diagnostic lab testing plus…

What could go right

  • BioReference lab volume growth
  • Pharma partnership royalty/milestone income

What could go wrong

  • Diversified/unfocused business model
  • Pharma pipeline/regulatory risk

Moat: none (scale). Diversified but sub-scale mix of lab testing and pharma assets lacks a clear single competitive advantage.

Headquarters: Miami, Florida · Employees: 2,275

Named competitors

OPKO Health at a glance

Size OPKO Health (OPK) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.25B, the 2089th largest of 3,085 United States companies the cockpit tracks. Shares closed at $1.69 on 18 Nov 2026.

Performance Over six months the shares gained 37.4%, against +14.4% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue fell 21.9% over the last twelve months (peer median +9.2%); the operating margin is -29.1% (peer median 5.0%).

Valuation It trades at 2.8× enterprise value to sales against a peer median of 1.8× (6th most expensive of 21).

Capital Return on invested capital runs 19.9 points below its cost of capital (10.6% WACC).

Credit OPKO Health has 1 bond outstanding ($121M).

Short interest Short interest is 4.4% of the free float (30 Oct 2026).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026OPK 132Peer median 113
Six months, rebased to 100: OPKO Health against the median of its 20 peers (local-currency closes).

OPKO Health financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$502M$607M$713M$863M$1.00B
Revenue growth—-15%-17%-14%—
Gross profit$158M$128M$136M$232M$204M
EBITDA-$59.9M-$127M-$175M-$52.8M-$137M
Net income-$148M-$226M-$53.2M-$189M-$328M
Free cash flow-$135M-$191M-$208M-$44.5M-$120M
Capital expenditure$10.8M$12.3M$25.0M$16.3M$24.6M
Total debt$516M$397M$504M$327M$306M

Quarterly statements and history in the cockpit →

OPKO Health competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%METROPOLISPNTGDIACLARINUTXLMRI1833GDRXUSPH4544TDOCAGLWGS688315AHCOAMBEASNDAPSNLREGVIJAYAOPK6-month return →1-month return →
Up and to the right = strong over both horizons. OPKO Health is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%0×5×10×15×METROPOLISPNTGDIACLARINUTXLMRI1833GDRXUSPH4544AGLWGSSNDAPSNLREGVIJAYAOPKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. OPKO Health is the large dot.

OPKO Health competitors and peer comparison

Head to head with its named competitors (OPK vs LH vs DGX vs PFE)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
OPKO Health OPK$1.25B+37%-22%-29%2.8×n/a
Labcorp LH$30.1B+44%+6%11%2.5×14.5%
Quest Diagnostics DGX$28.6B+34%+9%15%2.9×7.2%
Pfizer PFE$160B+9%+1%26%3.3×-4.3%

How OPKO Health compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

OPKO Health against its 20 peers (data as of 18 Nov 2026)
MeasureOPKPeer medianRank in peer set
1-month return+1.8%-0.2%10th highest of 21
6-month return+37.4%+14.4%5th highest of 21
Distance from 52-week high-9.1%-23.8%6th highest of 21
Revenue growth (TTM)-21.9%+9.2%lowest of 21
Operating margin-29.1%5.0%2nd lowest of 21
EV / Sales2.8×1.8×6th most expensive of 21
ROIC minus cost of capital-19.9 pp-3.4 pp3rd lowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
OPKO Health OPKUnited States$1.25B+37%-22%-29%2.8×n/an/a
Metropolis Healthcare METROPOLIS.NSIndia$1.25B+11%+20%18%6.5×32.4%+10.5%
Pennant PNTGUnited States$1.26B+1%+39%6%1.5×20.7%+19.4%
Diagnostyka DIA.WAPoland$1.28B-6%+19%15%2.5×7.3%+18.9%
Clariane CLARI.PAFrance$1.32B-20%+1%6%1.6×6.8%+6.5%
Nutex Health NUTXUnited States$1.19B+42%-19%39%1.8×-18.0%+253.5%
Lumexa Imaging LMRIUnited States$1.35B+89%+8%2%2.1×n/an/a
Ping An Healthcare and Technology 1833.HKHong Kong$1.36B-47%+8%3%0.4×3.5%-5.1%
GoodRx GDRXUnited States$1.15B+33%-2%12%1.8×6.3%+7.7%
U.S. Physical Therapy USPHUnited States$1.42B+53%+10%10%2.6×18.8%+13.0%
H.U.Group 4544.TJapan$1.44B+24%+1%3%1.0×9.7%+2.1%
Teladoc Health TDOCUnited States$1.47B+24%-2%-5%0.7×-6.4%+18.3%
agilon health AGLUnited States$1.52B+12%+2%-2%0.2×n/an/a
GeneDx WGSUnited States$1.56B+16%+15%-14%3.5×n/an/a
Novogene 688315.SSChina$1.01B+13%+6%7%2.2×13.9%+8.2%
AdaptHealth AHCOUnited States$1.01B-30%-3%3%0.9×16.8%+25.2%
Ambea AMBEA.STSweden$1.59B+28%+11%9%1.7×1.1%+7.7%
Sonida Senior Living SNDAUnited States$1.59B-11%+70%-8%4.8×n/an/a
Personalis PSNLUnited States$1.62B+88%+17%-157%18.2×n/an/a
Regis Healthcare REG.AXAustralia$962M-28%+17%4%0.9×13.3%+14.4%
Vijaya Diagnostic Centre VIJAYA.NSIndia$1.69B+18%+24%32%17.5×40.4%+16.7%

OPKO Health bonds and credit

OPKO Health has 1 bond outstanding with $121M face value.

Every bond, yield and spread in the cockpit →

Questions

Who are OPKO Health's main competitors?
Named competitors: Labcorp (LH), Quest Diagnostics (DGX), Pfizer (PFE). The cockpit's measured peer set (industry) also includes Metropolis Healthcare (METROPOLIS.NS), Pennant (PNTG), Diagnostyka (DIA.WA), Clariane (CLARI.PA), Nutex Health (NUTX), Lumexa Imaging (LMRI).
Is OPKO Health expensive compared with its peers?
On ev / sales it trades at 2.8× against a peer median of 1.8×, 6th most expensive of 21 in its peer set.
How has OPKO Health stock performed?
Over six months to 18 Nov 2026 the shares returned +37.4% against +14.4% for the median peer; over one year +33.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.